Shubham Pant, MD, Highlights the Potential of ELI-002 2P to Treat MRD in KRAS-Mutant Solid Malignancies
Cancer Network,
Shubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with…
First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors.
Overview of attention for article published in Journal of Clinical Oncology, June 2022
Altmetric Badge
About this Attention Score
-
Good Attention Score compared to outputs of the same age (70th percentile)
-
Average Attention Score compared to outputs of the same age and source
Readers on
- mendeley
- 17 Mendeley